FDA grants Breakthrough Therapy Designation for Roche’s Tecentriq in combination with Avastin as first-line treatment for advanced or metastatic hepatocellular carcinoma (HCC)

FDA grants Breakthrough Therapy Designation for Roche’s Tecentriq in combination with Avastin as first-line treatment for advanced or metastatic hepatocellular carcinoma (HCC)

19 July 2018 Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) as an initial (first-line) treatment for people with advanced

University of Missouri School of Medicine, Roche collaborate on first US implementation of tumor board software that improves treatment decision process for cancer patients

University of Missouri School of Medicine, Roche collaborate on first US implementation of tumor board software that improves treatment decision process for cancer patients

June 19, 2018 MU pilots Roche’s cloud-based NAVIFY Tumor Board solution to streamline and standardize data collection and presentation, enabling faster, better collaboration among oncology care teams INDIANAPOLIS and COLUMBIA, Mo., June 19, 2018 /PRNewswire/ — Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the

Roche introduces first self-testing device for Warfarin monitoring with built in Bluetooth® technology

Roche introduces first self-testing device for Warfarin monitoring with built in Bluetooth® technology

CoaguChek® Vantus system enables wireless reporting of INR results, making it easier for patients to accurately report their results. INDIANAPOLIS, June 11, 2018 /PRNewswire/ — Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today plans to launch the CoaguChek Vantus system, the first self-testing

Follow-up phase III data showed Roche’s Alecensa helped people with ALK-positive metastatic non-small cell lung cancer live a median of almost three years without their disease worsening or death

Basel, 17 May 2018 Investigator-assessed longer follow-up of the ALEX study demonstrated sustained benefit in the reduction of the risk of disease progression or death (57%) for people treated with Alecensa Alecensa more than tripled median progression-free survival (PFS) (34.8

Phase III IMpower150 study showed Roche’s Tecentriq and Avastin plus carboplatin and paclitaxel helped people with a specific type of metastatic lung cancer live significantly longer compared to Avastin plus carboplatin and paclitaxel

Basel, 17 May 2018 A survival advantage for the Tecentriq and Avastin combination regimen was observed in all pre-specified exploratory patient subgroups analysed, including people with EGFR and ALK mutations, liver metastases and those with varying levels of PD-L1 expression

Roche to present new phase III data for Hemlibra in people with haemophilia A at the World Federation of Hemophilia 2018 World Congress

Basel, 14 May 2018 Data include results from HAVEN 3 study in people with haemophilia A without factor VIII inhibitors and HAVEN 4 study in people with haemophilia A with or without factor VIII inhibitors Ongoing Hemlibra clinical development programme

Roche provides update on Phase III study of Tecentriq (atezolizumab) and Cotellic (cobimetinib) in people with heavily pre-treated locally advanced or metastatic colorectal cancer

Basel, 10 May 2018 Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMblaze370 study evaluating the combination of Tecentriq® (atezolizumab) and Cotellic® (cobimetinib) did not meet its primary endpoint of overall survival (OS) compared to regorafenib.

Roche to present new data from its industry-leading oncology portfolio at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting

Basel, 08 May 2018 New and updated pivotal combination data from the Tecentriq lung programme, including overall survival (OS) results from IMpower150 and progression free survival (PFS) results from IMpower131 New, longer follow-up data from the Phase III ALEX study

FDA grants priority review to Roche’s cancer immunotherapy TECENTRIQ (atezolizumab) for initial treatment of people with a specific type of metastatic lung cancer

Basel, 07 May 2018 Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) and granted Priority Review for TECENTRIQ® (atezolizumab), in combination with Avastin®

CHMP recommends EU approval of Roche’s Perjeta for post-surgery treatment of HER2-positive early breast cancer at high risk of recurrence

In the large phase III APHINITY study, the combination of Perjeta, Herceptin and chemotherapy significantly reduced the risk of invasive breast cancer recurrence or death by 19% compared to Herceptin and chemotherapy alone in the overall study population In the

New OCREVUS (ocrelizumab) data at AAN demonstrate significant reductions in disease activity and disability progression in relapsing multiple sclerosis

Four years of continuous treatment with OCREVUS showed a sustained reduction in underlying disease activity in relapsing MS (RMS) in analysis from the open-label extension period Additional analyses show OCREVUS delayed cognitive decline and improved cognitive function in RMS, as

FDA grants Breakthrough Therapy Designation for Roche’s Hemlibra in haemophilia A without inhibitors

Designation based on phase III HAVEN 3 study demonstrating Hemlibra prophylaxis significantly reduced bleeds compared to no prophylaxis First medicine to show superior efficacy compared to prior factor VIII prophylaxis in an intra-patient comparison Basel, 17 April 2018 Roche (SIX:

Roche to present new data at AAN highlighting extensive research for OCREVUS and expanding neuroscience pipeline

Breadth of data will reinforce efficacy and safety of OCREVUS in relapsing and primary progressive multiple sclerosis and demonstrate its benefits in slowing disability progression, including new cognitive and biomarker results Important research in Alzheimer’s disease, Huntington’s disease, Spinal Muscular